David A. Siegel Vera Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 6,000 shares of VERA stock, worth $253,740. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,000
Previous 74,500
91.95%
Holding current value
$253,740
Previous $2.7 Million
90.17%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding VERA
# of Institutions
184Shares Held
55.2MCall Options Held
134KPut Options Held
156K-
Avoro Capital Advisors LLC New York, NY4.31MShares$182 Million2.87% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.94MShares$167 Million0.02% of portfolio
-
Black Rock Inc. New York, NY3.34MShares$141 Million0.0% of portfolio
-
Abingworth LLP London, X02.96MShares$125 Million19.0% of portfolio
-
Sofinnova Investments, Inc. Menlo Park, CA2.79MShares$118 Million11.68% of portfolio
About Vera Therapeutics, Inc.
- Ticker VERA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,042,300
- Market Cap $1.14B
- Description
- Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...